Advanced search
1 file | 423.80 KB Add to list

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma

Author
Organization
Abstract
Abstract: Rationale: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF), which originates from the same precursor protein, is potentially more sensitive, yet lacks validation. Objectives: To analyze the diagnostic performance of MPF as an MPM biomarker and compare this performance with SM. Methods: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85). Sera were analyzed for SM and MPF levels using the Mesomark and Human MPF ELISA kit, respectively. Measurements and Main Results: SM and MPF levels differed significantly between patients with M PM and participants from each other cohort (P < 0.001). Receiver operating characteristics curve analysis did not reveal a significant difference between both markers in area under curve (AUC) for distinguishing MPM from all cohorts jointly (SM = 0.871, MPF = 0.849; P = 0.28). At 95% specificity, SM and MPF had a sensitivity of 64% (cutoff = 2.00 nmol/L) and 68% (cutoff = 12.38 ng/ml), respectively. Combining both markers did not improve the diagnostic performance. Conclusions: In this prospective multicenter study, MPF is validated as a highly performant MPM biomarker. The similar AUC values of SM and MPF, together with the limited difference in sensitivity, show that both serum biomarkers have an equivalent diagnostic performance.
Keywords
ASBESTOS-RELATED MESOTHELIOMA, MALIGNANT PLEURAL MESOTHELIOMA, SERUM MESOTHELIN, MOLECULAR-CLONING, OVARIAN-CARCINOMA, ERC, N-ERC/MESOTHELIN, TUMOR-MARKER, FAMILY PROTEINS, CELL-LINE, LUNG-CANCER, soluble mesothelin related protein, sensitivity, biomarkers, pleural malignancy

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 423.80 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hollevoet, Kevin, Kristiaan Nackaerts, Joel Thimpont, et al. “Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma.” AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 181.6 (2010): 620–625. Print.
APA
Hollevoet, K., Nackaerts, K., Thimpont, J., Germonpre, P., Bosquee, L., De Vuyst, P., Legrand, C., et al. (2010). Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 181(6), 620–625.
Chicago author-date
Hollevoet, Kevin, Kristiaan Nackaerts, Joel Thimpont, Paul Germonpre, Lionel Bosquee, Paul De Vuyst, Catherine Legrand, et al. 2010. “Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma.” American Journal of Respiratory and Critical Care Medicine 181 (6): 620–625.
Chicago author-date (all authors)
Hollevoet, Kevin, Kristiaan Nackaerts, Joel Thimpont, Paul Germonpre, Lionel Bosquee, Paul De Vuyst, Catherine Legrand, Eliane Kellen, Yoshiro Kishi, Joris Delanghe, and Jan P van Meerbeeck. 2010. “Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma.” American Journal of Respiratory and Critical Care Medicine 181 (6): 620–625.
Vancouver
1.
Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2010;181(6):620–5.
IEEE
[1]
K. Hollevoet et al., “Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma,” AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 181, no. 6, pp. 620–625, 2010.
@article{1181437,
  abstract     = {Abstract: Rationale: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF), which originates from the same precursor protein, is potentially more sensitive, yet lacks validation.
Objectives: To analyze the diagnostic performance of MPF as an MPM biomarker and compare this performance with SM.
Methods: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85). Sera were analyzed for SM and MPF levels using the Mesomark and Human MPF ELISA kit, respectively.
Measurements and Main Results: SM and MPF levels differed significantly between patients with M PM and participants from each other cohort (P < 0.001). Receiver operating characteristics curve analysis did not reveal a significant difference between both markers in area under curve (AUC) for distinguishing MPM from all cohorts jointly (SM = 0.871, MPF = 0.849; P = 0.28). At 95% specificity, SM and MPF had a sensitivity of 64% (cutoff = 2.00 nmol/L) and 68% (cutoff = 12.38 ng/ml), respectively. Combining both markers did not improve the diagnostic performance.
Conclusions: In this prospective multicenter study, MPF is validated as a highly performant MPM biomarker. The similar AUC values of SM and MPF, together with the limited difference in sensitivity, show that both serum biomarkers have an equivalent diagnostic performance.},
  author       = {Hollevoet, Kevin and Nackaerts, Kristiaan and Thimpont, Joel and Germonpre, Paul and Bosquee, Lionel and De Vuyst, Paul and Legrand, Catherine and Kellen, Eliane and Kishi, Yoshiro and Delanghe, Joris and van Meerbeeck, Jan P},
  issn         = {1073-449X},
  journal      = {AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE},
  keywords     = {ASBESTOS-RELATED MESOTHELIOMA,MALIGNANT PLEURAL MESOTHELIOMA,SERUM MESOTHELIN,MOLECULAR-CLONING,OVARIAN-CARCINOMA,ERC,N-ERC/MESOTHELIN,TUMOR-MARKER,FAMILY PROTEINS,CELL-LINE,LUNG-CANCER,soluble mesothelin related protein,sensitivity,biomarkers,pleural malignancy},
  language     = {eng},
  number       = {6},
  pages        = {620--625},
  title        = {Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma},
  url          = {http://dx.doi.org/10.1164/rccm.200907-1020OC},
  volume       = {181},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: